115 related articles for article (PubMed ID: 35822500)
1. Establishing and characterizing a novel doxorubicin-resistant acute myeloid leukaemia cell line.
Castro I; Lopes-Rodrigues V; Branco H; Vasconcelos MH; Xavier CPR
J Chemother; 2023 Jul; 35(4):307-321. PubMed ID: 35822500
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance.
Baran Y; Gür B; Kaya P; Ural AU; Avcu F; Gündüz U
Hematology; 2007 Dec; 12(6):511-7. PubMed ID: 17852453
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
Kostrzewa-Nowak D; Tarasiuk J
Anticancer Res; 2021 Mar; 41(3):1429-1438. PubMed ID: 33788734
[TBL] [Abstract][Full Text] [Related]
4. The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines.
Kostrzewa-Nowak D; Paine MJ; Wolf CR; Tarasiuk J
Br J Cancer; 2005 Jul; 93(1):89-97. PubMed ID: 15942634
[TBL] [Abstract][Full Text] [Related]
5. Combined Fourier transform infrared and Raman spectroscopic approach for identification of multidrug resistance phenotype in cancer cell lines.
Krishna CM; Kegelaer G; Adt I; Rubin S; Kartha VB; Manfait M; Sockalingum GD
Biopolymers; 2006 Aug; 82(5):462-70. PubMed ID: 16493658
[TBL] [Abstract][Full Text] [Related]
6. The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
Maruszewska A; Kostrzewa-Nowak D; Adamus J; Czupryńska K; Maryniak D; Gebicki J; Tarasiuk J
J Pharm Pharmacol; 2008 May; 60(5):647-53. PubMed ID: 18416942
[TBL] [Abstract][Full Text] [Related]
7. In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells.
Zhang L; Wang Z; Khishignyam T; Chen T; Zhou C; Zhang Z; Jin M; Wang R; Qiu Y; Kong D
Biomed Pharmacother; 2018 Jul; 103():1069-1078. PubMed ID: 29710665
[TBL] [Abstract][Full Text] [Related]
8. Targeting biliverdin reductase overcomes multidrug resistance in leukemia HL60 cells.
Kim SS; Seong S; Lim SH; Kim SY
Anticancer Res; 2013 Nov; 33(11):4913-9. PubMed ID: 24222129
[TBL] [Abstract][Full Text] [Related]
9. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells.
Wada H; Saikawa Y; Niida Y; Nishimura R; Noguchi T; Matsukawa H; Ichihara T; Koizumi S
Exp Hematol; 1999 Jan; 27(1):99-109. PubMed ID: 9923448
[TBL] [Abstract][Full Text] [Related]
10. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase. Implications for increasing its ability to inhibit the growth of sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Paine MJ; Korytowska A; Serwatka K; Piotrowska S; Wolf CR; Tarasiuk J
Cancer Lett; 2007 Jan; 245(1-2):252-62. PubMed ID: 16574318
[TBL] [Abstract][Full Text] [Related]
11. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
12. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
[TBL] [Abstract][Full Text] [Related]
13. MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.
Wang CC; Liu HE; Lee YL; Huang YW; Chen YJ; Liou JP; Huang HM
Tumour Biol; 2016 May; 37(5):6065-72. PubMed ID: 26608370
[TBL] [Abstract][Full Text] [Related]
14. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Tarasiuk J
Eur J Pharmacol; 2013 Dec; 721(1-3):141-50. PubMed ID: 24076328
[TBL] [Abstract][Full Text] [Related]
15. Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia.
Ma H; Zhou H; Song X; Shi S; Zhang J; Jia L
Oncogene; 2015 Feb; 34(6):726-40. PubMed ID: 24531716
[TBL] [Abstract][Full Text] [Related]
16. Retaining cytotoxic activity of anthrapyridone CO1 against multidrug resistant cells is related to the ability to induce concomitantly apoptosis and lysosomal death of leukaemia HL60/VINC and HL60/DOX cells.
Nowak R; Tarasiuk J
J Pharm Pharmacol; 2013 Jun; 65(6):855-67. PubMed ID: 23647679
[TBL] [Abstract][Full Text] [Related]
17. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
18. Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells.
Nowak R; Tarasiuk J
Anticancer Drugs; 2012 Apr; 23(4):380-92. PubMed ID: 22198116
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells.
Łubgan D; Jóźwiak Z; Grabenbauer GG; Distel LV
Cell Mol Biol Lett; 2009; 14(1):113-27. PubMed ID: 18850074
[TBL] [Abstract][Full Text] [Related]
20. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
